152513-88-7

Basic information

• Product Name: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI);7-tert-Butoxycarbonylamino-5-azaspiro[2.4]heptane;Tert-butyl 5-azaspiro[2.4]heptan-7-ylcarbamate;CarbaMic acid,-5-azaspiro[2.4]hept-7-yl-, 1,1-diMethylethyl ester;(5-Aza-spiro[2.4]hept-7-yl)-carbamic acid tert-butyl ester
• CAS NO: 152513-88-7
• Molecular Formula: C₁₁H₂₀N₂O₂
• Molecular Weight: 212.2887
• Product Categories: N-BOC
• Mol File: 152513-88-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 329.029 °C at 760 mmHg
• Flash Point: 152.791 °C
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.513
• PKA: 12.39±0.40(Predicted)
• CAS DataBase Reference: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(152513-88-7)
• EPA Substance Registry System: Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI)(152513-88-7)

Safety Data

• Hazardous Substances Data: 152513-88-7(Hazardous Substances Data)

Usage

General Description

Carbamic acid, 5-azaspiro[2.4]hept-7-yl-, 1,1-dimethylethyl ester (9CI) is a chemical compound with the molecular formula C9H17NO2. It is an ester of carbamic acid and is also known as N-tert-butylcarbamic acid 5-azaspiro[2.4]hept-7-yl ester. This chemical is commonly used in the pharmaceutical industry as a precursor in the synthesis of various pharmaceutical compounds. It is also used as an intermediate in organic synthesis and as a reagent in chemical research. Due to its potential pharmacological and biological activities, this compound is of interest to researchers and drug developers for its potential therapeutic applications. However, its specific uses and properties may vary depending on the context and the specific application.

InChI:InChI=1/C11H20N2O2/c1-10(2,3)15-9(14)13-8-6-12-7-11(8)4-5-11/h8,12H,4-7H2,1-3H3,(H,13,14)

Upstream product

• 129306-04-3 5-benzyl-5-azaspiro[2.4]heptane-4,7-dione 
• 129306-07-6 5-benzyl-5-azaspiro[2.4]heptane-7-amine 
• 129306-06-5 (7E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one 
• 129306-13-4 5-phenylmethyl-N-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-7-amine 

Downstream Products

• 1000062-33-8 (2S,4S)-2-[7-(t-butyloxycarbonylamino-5-azaspiro[2.4]heptane)carbonyl]-4-tritylthio-1-(allyloxycarbonyl)pyrrolidine 

Relevant articles and documents

Fluoroquinolone derivative and application of fluoroquinolone derivative as antibacterial drug

The invention discloses a fluoroquinolone derivative which is characterized in that the fluoroquinolone derivative has a structure as shown in a general formula (I) or an isomer thereof or a pharmaceutically acceptable salt thereof or a mixture of the structures. Wherein R1 is selected from C1-C4 alkyl groups; or R1 is selected from a spiro or bridged alkane chain which shares one or two carbon atoms with pyrrolidinyl connected with R1, and R1 contains 1-6 carbon atoms; O atom on the benzene ring is alternatively connected with R2 or R3: when the O atom on the benzene ring is connected with R2, R2 is selected from substituted or unsubstituted C2-C4 alkylene, and R3 does not exist; when O atom is connected with R3, R2 is selected from C3-C6 cycloalkyl, and R3 is selected from C1-C3 alkyl. The fluoroquinolone derivative provided by the invention has a good inhibition effect on escherichia coli, staphylococcus aureus and tetracoccus, and provides a certain reference for further design of quinolone compound structures.

SUBSTITUTED ALKYNYL PYRIDINE COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl pyridine compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Optically active pyridonecarboxylic acid derivatives

N1 -(1,2-cis-2-halogenocyclopropyl)-substituted pyridonecarboxylic acid derivatives represented by the following formula (I) the terms of which are defined in the specification and the salts thereof are disclosed: STR1 These compounds have pate